These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12205699)

  • 1. Likelihood methods for measuring statistical evidence.
    Blume JD
    Stat Med; 2002 Sep; 21(17):2563-99. PubMed ID: 12205699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpreting statistical evidence with empirical likelihood functions.
    Zhang Z
    Biom J; 2009 Aug; 51(4):710-20. PubMed ID: 19650056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical evidence for GLM regression parameters: a robust likelihood approach.
    Blume JD; Su L; Olveda RM; McGarvey ST
    Stat Med; 2007 Jul; 26(15):2919-36. PubMed ID: 17211856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
    Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
    J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the design and analysis of randomized clinical trials with multiple endpoints.
    Tang DI; Geller NL; Pocock SJ
    Biometrics; 1993 Mar; 49(1):23-30. PubMed ID: 8513104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retrolective study design -- a new tool of evidence-based medicine].
    Martin S
    Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S86-90. PubMed ID: 15988675
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
    Manchikanti L; Datta S; Smith HS; Hirsch JA
    Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 2: Statistical considerations.
    Ball G; Piller LB
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S5-7. PubMed ID: 21664986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring and illustrating statistical evidence in a cost-effectiveness analysis.
    Hoch JS; Blume JD
    J Health Econ; 2008 Mar; 27(2):476-95. PubMed ID: 18179834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of ADVANCE trial conducted in type 2 diabetic patients].
    Ter Arkh; 2008; 80(1):88. PubMed ID: 18326237
    [No Abstract]   [Full Text] [Related]  

  • 11. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Is an evidence-based therapy of inpatients with type 2 diabetes possible from studies used for formulating therapy guidelines?].
    Häuser W; Ziehl S; Poltorak P; Grandt D
    Dtsch Med Wochenschr; 2005 Apr; 130(17):1069-73. PubMed ID: 15841421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of multi-centre trials with binary response.
    Dragalin V; Fedorov V
    Stat Med; 2006 Aug; 25(16):2701-19. PubMed ID: 16252268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculations in the presence of competing risks.
    Latouche A; Porcher R
    Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Settling the UGDP controversy"?
    Bradley RF; Dolger H; Forsham PH; Seltzer H
    JAMA; 1975 May; 232(8):813-7. PubMed ID: 1091759
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: Settling the UGDP controversy.
    Chalmers TC
    JAMA; 1975 Feb; 231(6):624-5. PubMed ID: 1172848
    [No Abstract]   [Full Text] [Related]  

  • 17. Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs.
    Atkins D
    Med Care; 2007 Oct; 45(10 Supl 2):S16-22. PubMed ID: 17909376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints.
    Alonso A; Molenberghs G; Burzykowski T; Renard D; Geys H; Shkedy Z; Tibaldi F; Abrahantes JC; Buyse M
    Biometrics; 2004 Sep; 60(3):724-8. PubMed ID: 15339295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials.
    O'Malley AJ; Normand SL
    Biometrics; 2005 Jun; 61(2):325-34. PubMed ID: 16011678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.